Thornburg Investment Management Inc. Has $3.89 Million Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Thornburg Investment Management Inc. grew its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 138.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 40,345 shares of the biotechnology company’s stock after acquiring an additional 23,406 shares during the quarter. Thornburg Investment Management Inc.’s holdings in Sarepta Therapeutics were worth $3,890,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. First Turn Management LLC acquired a new stake in shares of Sarepta Therapeutics during the 4th quarter valued at $19,660,000. Mitsubishi UFJ Asset Management Co. Ltd. raised its position in shares of Sarepta Therapeutics by 65.2% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,108 shares of the biotechnology company’s stock worth $291,000 after acquiring an additional 1,227 shares during the last quarter. Principal Financial Group Inc. lifted its stake in shares of Sarepta Therapeutics by 125.3% in the fourth quarter. Principal Financial Group Inc. now owns 49,539 shares of the biotechnology company’s stock worth $4,777,000 after acquiring an additional 27,549 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Sarepta Therapeutics by 10.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 224,201 shares of the biotechnology company’s stock valued at $21,621,000 after acquiring an additional 20,923 shares during the last quarter. Finally, Jump Financial LLC acquired a new stake in Sarepta Therapeutics during the 4th quarter valued at approximately $1,357,000. Institutional investors own 86.68% of the company’s stock.

Insider Activity at Sarepta Therapeutics

In related news, insider Bilal Arif sold 2,000 shares of the business’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $128.84, for a total value of $257,680.00. Following the sale, the insider now directly owns 26,836 shares in the company, valued at approximately $3,457,550.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, insider Bilal Arif sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $128.84, for a total value of $257,680.00. Following the sale, the insider now owns 26,836 shares of the company’s stock, valued at $3,457,550.24. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Kathryn Jean Boor sold 761 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $122.93, for a total transaction of $93,549.73. Following the sale, the director now owns 7,516 shares in the company, valued at $923,941.88. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 25,731 shares of company stock worth $3,248,319. Insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Stock Down 0.9 %

SRPT traded down $1.24 during midday trading on Friday, reaching $131.50. 54,198 shares of the company were exchanged, compared to its average volume of 1,016,952. The company has a market cap of $12.43 billion, a price-to-earnings ratio of 1,206.73 and a beta of 0.95. Sarepta Therapeutics, Inc. has a one year low of $55.25 and a one year high of $152.21. The company’s fifty day moving average price is $126.36 and its 200 day moving average price is $112.14. The company has a debt-to-equity ratio of 1.18, a quick ratio of 3.44 and a current ratio of 4.05.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.84. The firm had revenue of $413.50 million during the quarter, compared to analyst estimates of $375.52 million. Sarepta Therapeutics had a return on equity of 2.20% and a net margin of 1.20%. The business’s revenue was up 63.1% compared to the same quarter last year. During the same period last year, the firm posted ($1.44) EPS. As a group, analysts expect that Sarepta Therapeutics, Inc. will post 2.68 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on SRPT shares. Evercore ISI boosted their price target on shares of Sarepta Therapeutics from $108.00 to $138.00 and gave the stock an “in-line” rating in a research report on Tuesday, February 20th. Wedbush reaffirmed an “outperform” rating and set a $224.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, February 29th. Barclays lifted their price objective on Sarepta Therapeutics from $141.00 to $185.00 and gave the stock an “overweight” rating in a research report on Thursday, February 29th. JPMorgan Chase & Co. cut their target price on Sarepta Therapeutics from $177.00 to $175.00 and set an “overweight” rating on the stock in a research report on Friday, May 3rd. Finally, TheStreet upgraded Sarepta Therapeutics from a “d” rating to a “c-” rating in a report on Monday, March 4th. Three investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $163.94.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.